Researchers at the University of Virginia, in collaboration with Manchester, UK-based APIS Assay Technologies Ltd., have discovered Hormone-Upregulated lncRNA within the lymphocyte-specific protein tyrosine kinase is detectable in non-invasive prostate cancer patient samples.
Cancer patients and their medical teams found it beneficial when patients shared their symptoms in real time using a web- or telephone-based reporting system, according to a national multi-institutional study, the PRO-TECT trial.
Researchers found that colon cancer patients achieve better five-year survival rates when the surgeons who treat them are rated as highly skilled.
Researchers found that active surveillance is safe for African Americans with low-risk prostate cancer.
Researchers found that pancreatic cancer cells avert starvation by signaling to nerves, which grow deeply into dense tumors and secrete nutrients.
Through large-scale profiling of protein changes in response to drug treatments in cancer cell lines, researchers at MD Anderson Cancer Center have generated a resource to aid in predicting drug sensitivity, to understand therapeutic resistance mechanisms and to identify optimal combination treatment strategies.
A draft guideline by the United States Preventive Services Task Force recommends that colorectal cancer screening should begin five years earlier—at age 45 for average-risk individuals.
A study by researchers at Thomas Jefferson University and Sidney Kimmel Cancer Center – Jefferson Health demonstrates that although Black patients are now more likely to receive the most effective treatment in non-small cell lung cancer than a decade ago, disparities persist.
Winship Cancer Institute of Emory University researchers found that treatment based on advanced molecular imaging can improve disease-free survival rates for men with prostate cancer with recurring cancer.
The New York Proton Center is joining the first national randomized clinical trial to evaluate the efficacy of proton therapy compared to traditional radiotherapy for patients with locally advanced breast cancer.